Addenbrooke’s doctor publishes breakthrough cancer findings

PUBLISHED: 18:31 01 August 2018

Addenbrooke's Hospital [Picture: Google]

Addenbrooke's Hospital [Picture: Google]

Archant

A doctor at Addenbrooke’s Hospital in Cambridge has published breakthrough findings by Cambridge academics, which could further help clinicians in the battle against cancer.

Wellcome Clinical Fellow and Addenbrooke’s Hospital urology registrar Dr Harveer Dev. Picture: CUHWellcome Clinical Fellow and Addenbrooke’s Hospital urology registrar Dr Harveer Dev. Picture: CUH

Researchers have discovered a novel protein complex called Shieldin which if tested could help experts better predict patients’ response to revolutionary new anti-cancer drugs.

Wellcome Clinical Fellow and Addenbrooke’s Hospital urology registrar Harveer Dev – the study’s lead author – has just published these findings in the scientific journal, Nature Cell Biology.

Professor Steve Jackson’s group from the University of Cambridge had previously discovered a new class of cancer treating drugs called PARP –Poly ADP-ribose polymerase) inhibitors – which are highly effective in cancers with mutations in the tumour suppressor gene BRCA1.

However, drug resistance is a common response, and so researchers, including Dr Dev, set out to establish how resistance might develop.

Using state-of-the-art gene editing technology, the team scanned the human genome and looked for factors which could cause drug resistance in cancer cells that lacked BRCA1. One of these factors was the previously uncharacterised Shieldin complex.

Dr Dev, who is a member of Addenbrooke’s Academic Urology Group, said there was good reason for the research – BRCA1 and other related mutations are found in a significant number of cancers, particularly in the breast, ovaries and prostate.

He said “This is an important step forward in our understanding of how cancers respond to this treatment. The idea of publishing it is to share widely the findings with those in the clinical and scientific community.

“We know that those tumours with normal Shieldin levels initially respond to PARP inhibitors. However, if the Shieldin levels are low to begin with, or decrease following treatment, then resistance is observed. This means testing the Shieldin status of BRCA1 mutated tumours might be useful in predicting responsiveness to therapy.”

Professor Jackson added: “We should be able to better predict the response of a patient’s tumour to specific therapies like PARP inhibitors, and ultimately personalise cancer therapy to achieve the maximum benefit for each individual.”

The study was funded by the Wellcome Trust and Cancer Research UK.

0 comments

Welcome , please leave your message below.

Optional - JPG files only
Optional - MP3 files only
Optional - 3GP, AVI, MOV, MPG or WMV files
Comments

Please log in to leave a comment and share your views with other Royston Crow visitors.

We enable people to post comments with the aim of encouraging open debate.

Only people who register and sign up to our terms and conditions can post comments. These terms and conditions explain our house rules and legal guidelines.

Comments are not edited by Royston Crow staff prior to publication but may be automatically filtered.

If you have a complaint about a comment please contact us by clicking on the Report This Comment button next to the comment.

Not a member yet?

Register to create your own unique Royston Crow account for free.

Signing up is free, quick and easy and offers you the chance to add comments, personalise the site with local information picked just for you, and more.

Sign up now

More news stories

Saturday, October 20, 2018

The MP for South Cambridgeshire has organised a public meeting for constituents to discuss their views on Brexit.

Friday, October 19, 2018

The Bassingbourn Village College Spanish exchange trip has run for a “very successful” second time to Albacete, in the sunny south-west of Spain.

Friday, October 19, 2018

Saving for a prolonged period of travel is essential, says our financial columnist Peter Sharkey. And now might just be the best time to go.

Friday, October 19, 2018

Sandon schoolchildren have visited a farm in the village as part of their local history and geography project.

Most read stories

Show Job Lists

Digital Edition

Image
Read the Royston Crow e-edition E-edition

Newsletter Sign Up

Royston Crow weekly newsletter
Sign up to receive our regular email newsletter

Our Privacy Policy